[
    [
        {
            "time": "2018-01-02",
            "original_text": "The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Premix",
                    "Fast-Acting",
                    "Insulin"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "NVO’s Tresiba and Xultophy Could See Solid Growth in 2018",
            "features": {
                "keywords": [
                    "NVO",
                    "Tresiba",
                    "Xultophy",
                    "Solid Growth"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "NVO’s Tresiba and Xultophy Could See Solid Growth in 2018",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver",
            "features": {
                "keywords": [
                    "Oral Semaglutide",
                    "Novo Nordisk",
                    "Long-Term",
                    "Growth Driver"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]